GT Biopharma Inc
NASDAQ:GTBP
GT Biopharma Inc
Operating Income
GT Biopharma Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
GT Biopharma Inc
NASDAQ:GTBP
|
Operating Income
-$13.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-33%
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
See Also
What is GT Biopharma Inc's Operating Income?
Operating Income
-13.6m
USD
Based on the financial report for Dec 31, 2023, GT Biopharma Inc's Operating Income amounts to -13.6m USD.
What is GT Biopharma Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-33%
Over the last year, the Operating Income growth was 36%. The average annual Operating Income growth rates for GT Biopharma Inc have been -26% over the past three years , 9% over the past five years , and -33% over the past ten years .